La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Adaptimmune Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Adaptimmune Therapeutics..

Adaptimmune Therapeutics (NASDAQ:ADAP) Azioni, Catena delle Opzioni

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

Adapti Inc

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 8.5% to $1.15 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock rose 7.1% to $8.59. The market value of their outstanding shares is at $104.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.07% to $0.26. The company's market cap stands at $69.7 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) stock moved upwards by 6.58% to $5.5. The market value of their outstanding shares is at $30.2 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 5.91% to $0.33. The company's market cap stands at $1.4 million. </li>
<li>Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) stock increased by 5.52% to $4.2. The company's market cap stands at $292.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 16.3% to $0.03 during Thursday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Rein Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) shares declined by 12.7% to $1.72. The market value of their outstanding shares is at $38.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares decreased by 10.79% to $18.12. The company's market cap stands at $471.3 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 8.63% to $0.28. The market value of their outstanding shares is at $7.5 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock decreased by 8.19% to $4.15. The market value of their outstanding shares is at $388.2 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 6.52% to $0.14. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

BIAF

CMPS

HCAT

HCTI

LIMN

NCNA

NUWE

PLRZ

RNTX

SCLX

12 Health Care Stocks Moving In Thursday's After-Market Session

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Adaptimmune Therapeutics, presenting an average target of $1.52, a high estimate of $3.00, and a low estimate of $0.46. A negative shift in sentiment is evident as analysts have decreased the average price target by 35.59%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747256431_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Adaptimmune Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$0.46</td>
<td>$1.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.00</td>
<td>$1.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1.75</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1.40</td>
<td>$3.15</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptimmune Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Adaptimmune Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adaptimmune Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Adaptimmune Therapeutics's Background</h2>
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
<h3>Breaking Down Adaptimmune Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Adaptimmune Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1294.81% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Adaptimmune Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2303.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -161.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -26.35%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Adaptimmune Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 6.26. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics

Barclays analyst Peter Lawson maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Underweight and lowers the price target from $1 to $0.46.

News

Price Target

Barclays Maintains Underweight on Adaptimmune Therapeutics, Lowers Price Target to $0.46

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $1.5 to $1.

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1

WIIM

ADAP stock has given up its prior gain. Adaptimmune Therapeutics shares were trading higher after the company reported better-than-expected Q1 financial results.

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) by 75 percent. This is unchanged from the same period last year. The company reported quarterly sales of $7.29 million which beat the analyst consensus estimate of $6.17 million by 17.99 percent. This is a 28.30 percent increase over sales of $5.68 million the same period last year.

Earnings

Earnings Beats

Adaptimmune Therapeutics Q1 EPS $(0.03) Beats $(0.12) Estimate, Sales $7.29M Beat $6.17M Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Adaptimmune Therapeutics to report an earnings per share (EPS) of $-0.17.
The market awaits Adaptimmune Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.15, leading to a 3.86% increase in the share price on the subsequent day.
Here's a look at Adaptimmune Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.13</td>
<td>-0.08</td>
<td>-0.10</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.30</td>
<td>-0.07</td>
<td>0.24</td>
<td>-0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-23.0%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747083883_0.png" alt="eps graph" />
<h3>Market Performance of Adaptimmune Therapeutics's Stock</h3>
Shares of Adaptimmune Therapeutics were trading at $0.2926 as of May 09. Over the last 52-week period, shares are down 74.33%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ADAP/earnings">To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Adaptimmune Therapeutics's Earnings Forecast

<h3>Gainers</h3>
<ul>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares rose 13.2% to $2.75 during Wednesday's after-market session. The company's market cap stands at $382.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock increased by 11.55% to $5.31. The company's market cap stands at $250.8 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock increased by 8.61% to $0.35. The company's market cap stands at $25.0 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.6% to $0.28. The company's market cap stands at $73.8 million. </li>
<li>Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) stock increased by 7.18% to $4.64. The market value of their outstanding shares is at $270.6 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares rose 6.83% to $0.85. The company's market cap stands at $65.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares declined by 20.4% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 19.62% to $2.95. The company's market cap stands at $4.1 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.33% to $0.61. The market value of their outstanding shares is at $43.4 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares fell 8.03% to $7.34. The company's market cap stands at $347.8 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares fell 6.98% to $2.8. The market value of their outstanding shares is at $4.1 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock decreased by 6.12% to $1.8. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CADL

CLSD

CTOR

ENSC

NAYA

OVID

RLMD

SXTP

VNDA

ZYBT

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 73.1% to $0.8 during Friday's regular session. The company's market cap stands at $9.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock rose 43.62% to $34.9. The market value of their outstanding shares is at $454.1 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 37.05% to $0.52. The company's market cap stands at $1.7 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares rose 32.04% to $1.88. The company's market cap stands at $111.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock moved upwards by 23.95% to $3.57. The market value of their outstanding shares is at $54.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 22.34% to $1.15. The company's market cap stands at $15.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock declined by 44.3% to $0.48 during Friday's regular session. The market value of their outstanding shares is at $14.7 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 32.16% to $1.35. The market value of their outstanding shares is at $1.9 million. </li>
<li>Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) stock fell 22.62% to $5.27. The company's market cap stands at $195.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 22.2% to $0.27. The company's market cap stands at $8.1 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 22.11% to $0.44. The market value of their outstanding shares is at $2.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) shares decreased by 20.6% to $0.26. The market value of their outstanding shares is at $66.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALDX

APVO

KAPA

LFCR

NIVF

PRPH

RSLS

12 Health Care Stocks Moving In Friday's Intraday Session

4 analysts have shared their evaluations of Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1.91, with a high estimate of $3.00 and a low estimate of $1.40. A negative shift in sentiment is evident as analysts have decreased the average price target by 34.36%. 
<img src="https://www.benzinga.com/files/images/story/2025/1743512458_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Adaptimmune Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1.75</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1.40</td>
<td>$3.15</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Adaptimmune Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Adaptimmune Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Adaptimmune Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Adaptimmune Therapeutics Better</h2>
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
<h3>Unraveling the Financial Story of Adaptimmune Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Adaptimmune Therapeutics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1294.81%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Adaptimmune Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2303.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -161.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Adaptimmune Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -26.35%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Adaptimmune Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 6.26, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Adaptimmune Therapeutics Stock

HC Wainwright &amp; Co. analyst Arthur He maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and lowers the price target from $3.5 to $3.

HC Wainwright & Co. Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3

Guggenheim analyst Michael Schmidt maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and lowers the price target from $3 to $1.75.

Guggenheim Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $1.75

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $2 to $1.5.

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1.5

Scotiabank analyst George Farmer maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Sector Outperform and lowers the price target from $3.15 to $1.4.

Scotiabank Maintains Sector Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.4

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 226.4% to $1.73 during Thursday's regular session. The market value of their outstanding shares is at $19.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 205.28% to $1.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock moved upwards by 54.63% to $9.28. The company's market cap stands at $93.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 31.36% to $2.22. The company's market cap stands at $1.6 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock moved upwards by 27.84% to $11.98. The company's market cap stands at $98.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) stock moved upwards by 26.43% to $14.73. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 38.8% to $0.29 during Thursday's regular session. The company's market cap stands at $17.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 28.51% to $0.32. The market value of their outstanding shares is at $82.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares declined by 28.35% to $2.04. The company's market cap stands at $480.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 20.28% to $2.59. The company's market cap stands at $1.7 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 18.76% to $1.43. The market value of their outstanding shares is at $46.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 17.1% to $1.94. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

BDRX

CRVO

ELEV

OPTN

PSTV

RMTI

SPRY

VERO

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

Adaptimmune Therapeutics shares are trading lower after the company issued a business update ahead of its scheduled earnings report and said it will disclose doubt about its ability to continue as a going concern.

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.25% to 42,070.99 while the NASDAQ climbed 0.37% to 17,817.11. The S&amp;P 500 also rose, gaining, 0.28% to 5,689.83.
Check This Out: <a href="https://www.benzinga.com/25/03/44414809/tesla-to-450-here-are-10-top-analyst-forecasts-for-thursday">Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 0.7% on Thursday.
In trading on Thursday, materials shares fell by 0.3%.
Top Headline
Shares of Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) fell more than 7% on Thursday after the company reported results for the second quarter.
The company reported second-quarter 2025 earnings of $2.82 per share, slightly above the consensus of $2.81. The company reported sales of $16.66 billion, almost in line with the consensus of $16.62 billion and management guidance of $16.2 billion–$16.8 billion.
Accenture narrowed its fiscal year 2025 revenue growth outlook to 5%-7% in local currency, compared to prior guidance of 4%-7%. The company forecasts 2025 diluted earnings of $12.55-$12.79 per share compared to the consensus of $12.90.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SAG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares shot up 107% to $1.3995.</li>
<li>Shares of Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>)got a boost, surging 59% to $2.6900 after the company entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem&#8217;s PHEXXI.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares were also up, gaining 57% to $9.39 after Paratek Pharmaceuticals announced it will acquire the company in a deal worth $330 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares dropped 47% to $0.2501 after the company announced the discontinued development of EO-3021.</li>
<li>Shares of Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) were down 45% to $0.3570 after the company filed for Chapter 11 bankruptcy.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) was down, falling 31% to $0.3088 after the company issued fourth-quarter and full year 2024 business update.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $67.50 while gold traded down 0.1% at $3,040.20.
Silver traded down 0.6% to $33.985 on Thursday, while copper fell 0.4% to $5.0815.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX 40 fell 1.2% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 0.9%, while London's FTSE 100 slipped 0.1%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with China's Shanghai Composite Index falling 0.51%, Hong Kong's Hang Seng Index dipped 2.23% and India's BSE Sensex gaining 1.19%.
Economics
<ul>
<li>U.S. existing home sales increased by 4.2% from the previous month to an annualized rate of 4.26 million homes in February.</li>
<li>The U.S. current account deficit shrank by 2.0% to $303.9 billion in the fourth quarter, versus a revised deficit of $310.3 billion in the third quarter.</li>
<li>U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell to 12.5 in March from 18.1 in the previous month, versus market estimates of 8.5.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415297/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q2 Earnings</a></li>
</ul>

Photo: Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BHIL

Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results

Corporate updates
<ul>
<li>Executed on 29% reduction in headcount in Q1 2025 as part of approximately $300 million in aggregate cost savings over the next four years to enable goal of achieving operating profitability during 2027</li>
<li>Implemented additional cost reduction for the PRAME and CD70 programs. The Company anticipates this will generate an additional $75m to $100m in aggregate cost savings over the next 4 years</li>
<li>Engaged TD Cowen to evaluate strategic options for the Company and for all its programs</li>
</ul>

Health Care

General

Adaptimmune Says 2024 Annual Report, Set To Be Filed On Monday, March 24, Will State That There Are Serious Concerns About The Company's Ability To Stay In Business, At The End Of 2024, Adaptimmune Had Total Liquidity Of $152M

Press Releases

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune Reports Q3 2024 Financial and Business Updates

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Comments

Adaptimmune Therapeutics

Adaptimmune Therapeutics (ADAP) Opzioni

Adaptimmune Therapeutics (NASDAQ:ADAP) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO